WilliamGraydonHarkerMD

Oncology • Salt Lake City, UT

Physician

Join to view full profile

Are you Dr. Harker?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 53 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
3838 S 700 E
Suite 100
Salt Lake City, UT 84106
Phone+1 801-269-0231

Fax+1 801-269-0304
Is this information wrong?

Summary

Dr. William Harker, MD is an oncologist in Salt Lake City, Utah. He is currently licensed to practice medicine in Utah. He is affiliated with Lakeview Hospital.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1980 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1975 - 1978
University of Utah School of MedicineClass of 1975

Certifications & Licensure

UT State Medical License 1984 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

107 citations
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
Gabriel N. Hortobagyi, Catherine Van Poznak, W. Graydon Harker, William J. Gradishar, Helen K. Chew, Shaker R. Dakhil, Barbara Haley, Nicholas Sauter, Ramon Mohanlal, ...> ;JAMA Oncology. 2017 Jul 1
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With ...
Motzer, R. J.,Barrios, C. H.,Kim, T. M.,Falcon, S.,Cosgriff, T.,Harker, W. G.,Srimuninnimit, V.,Pittman, K.,Sabbatini, R.,Rha, S. Y.,Flaig, T. W.,Page, R.,Bavbek, S.,B...> ;J. Clin. Oncol.. 2014 Jul 23
138 citations
Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
Adam Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda D. Bosserman, Charles L. Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohn...> ;Cancer. 2012 Mar 1
Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC).
Borson R, Harker WG, Reeves JE, Drosick D, Beck JT, Hager SJ, Horvath WL, Bromund J, Zeigler H, Tai D, Yardley DA> ;J. Clin. Oncol.. 2011-05-20
Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally adv...
Whitehead RP, McCoy S, Wollner IS, Wong L, Harker WG, Hoff PM, Gold PJ, Billingsley KG, Blanke CD> ;J. Clin. Oncol.. 2006-06-20
Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr).
Berlin J, Neubauer M, Swanson P, Harker WG, Burris H, Hecht JR, Navale L> ;J. Clin. Oncol.. 2006-06-20
Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant le...
Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Lacerna L, Thomas E, Perez E> ;J. Clin. Oncol.. 2005-06-01
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
O' Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano M, Hurwitz H, Tchekmedyian NS, Ackerman J, De Jager RL, Eckhardt SG> ;J. Clin. Oncol.. 2004-07-15
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., Perez, E. A.> ;J Clin Oncol. 2007 Mar 1
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Leonard, R., O'Shaughnessy, J., Vukelja, S., Gorbounova, V., Chan-Navarro, C. A., Maraninchi, D., Barak-Wigler, N., McKendrick, J. J., Harker, W. G., Bexon, A. S., Twe...> ;Ann Oncol. 2006 Sep
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Vaughn, D. J., Brown, A. W., Harker, W. G., Huh, S., Miller, L., Rinaldi, D., Kabbinavar, F.> ;Cancer. 2004 Feb 15
43 citations
Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
M E Bauman, Joseph A. Holden, Karen A. Brown, W G Harker, Sherrie L. Perkins> ;Modern Pathology. 1997 Mar 1
Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
Bukowski, R. M., Wolfe, M., Levine, H. S., Crawford, D. E., Stephens, R. L., Gaynor, E., Harker, W. G.> ;J Clin Oncol. 1993 Jan
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks, M. K., Warmoth, M. R., Friche, E., Granzen, B., Bugg, B. Y., Harker, W. G., Zwelling, L. A., Futscher, B. W., Suttle, D. P., Beck, W. T.> ;Cancer Res. 1993 Mar 15
Peripherally inserted central venous catheters. Low-risk alternatives for ongoing venous access.
Merrell, S. W., Peatross, B. G., Grossman, M. D., Sullivan, J. J., Harker, W. G.> ;West J Med. 1994 Jan
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induc...
Hesketh, P. J., Harvey, W. H., Harker, W. G., Beck, T. M., Ryan, T., Bricker, L. J., Kish, J. A., Murphy, W. K., Hainsworth, J. D., Haley, B.> ;J Clin Oncol. 1994 Mar
Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., Pommier, Y.> ;Cancer Res. 1995 Mar 15
87 citations
Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzy...
W G Harker, D L Slade, R L Parr, P W Feldhoff, D M Sullivan, M H Holguin> ;Cancer Research. 1995 Apr 15
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
Hesketh, P. J., Beck, T., Uhlenhopp, M., Kris, M. G., Hainsworth, J. D., Harker, W. G., Cohen, J. R., Lester, E., Kessler, J. F., Griffen, D.> ;J Clin Oncol. 1995 Aug
Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in ...
Harker, W. G., Slade, D. L., Parr, R. L., Holguin, M. H.> ;Cancer Res. 1995 Nov 1
Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor, R., Slade, D. L., Fujimori, A., Pommier, Y., Harker, W. G.> ;Oncol Res. 1995
Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs.
Harker, W. G., MacKintosh, F. R., Sikic, B. I.> ;Cancer Res. 1983 Oct
5 citations
The Chemotherapy of Bladder Carcinoma: Systemic Therapy
W. G. Harker, F. M. Torti> ;Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 1983 Jan 1
9 citations
Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.
Frank M. Torti, W. Graydon Harker> ;Cancer Chemotherapy and Pharmacology. 1983 Jan 1
The effect of lithium upon granulocyte production in vitro and in vivo in the mouse.
Rothstein, G., Oshita, A. K., Harker, W. G., Lonngi, G., Christensen, R. D.> ;Adv Exp Med Biol. 1980
Join now to see all

Hospital Affiliations

Lakeview HospitalBountiful, Utah